Wednesday, June 10, 2026

pharma Β· Renal Transplantation Β· Rheumatoid Arthritis (RA)

Astellas Pharma

Astellas Pharma clinical programs β€” 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
NMPA registrant Type
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
20
Drugs
12
Patents
25
Intelligence Β· Clinical Programs

Astellas Pharma projects

20 ClinicalTrials.gov programs sponsored by Astellas Pharma.

Astellas Pharma has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ASP8825

    Astellas Pharma Inc

    Restless Legs Syndrome

    phase 3 small molecule completed

    1 trial
  2. Fezolinetant

    Astellas Pharma Inc

    Hot Flashes

    phase 3 small molecule completed

    1 trial
  3. Isavuconazole

    Astellas Pharma Inc

    Candidiasis, Invasive

    phase 3 small molecule completed

    1 trial
  4. Mirabegron

    Astellas Pharma Inc

    Overactive Bladder (OAB)

    phase 3 small molecule terminated

    1 trial
  5. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial
  6. Tacrolimus capsule

    Astellas Pharma Inc

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial
  7. YM060

    Astellas Pharma Inc

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial
  8. gilteritinib

    Astellas Pharma Inc

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule completed

    1 trial
  9. linaclotide

    Astellas Pharma Inc

    Chronic Constipation

    phase 3 small molecule completed

    1 trial
  10. tacrolimus

    Astellas Pharma Inc

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial
  11. ASP5094

    Astellas Pharma Inc

    Rheumatoid Arthritis (RA)

    phase 2 small molecule completed

    1 trial
  12. ASP8273

    Astellas Pharma Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial
  13. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial
  14. Tacrolimus

    Astellas Pharma Inc

    Bone Marrow Transplantation

    phase 2 small molecule completed

    1 trial
  15. YM150

    Astellas Pharma Inc

    Thromboembolism

    phase 2 small molecule completed

    1 trial
  16. ASP1941

    Astellas Pharma Inc

    Healthy

    phase 1 small molecule completed

    1 trial
  17. ESN364

    Astellas Pharma Inc

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  18. TRK-100STP (BERASUS LA)

    Astellas Pharma Inc

    Healthy

    phase 1 small molecule completed

    1 trial
  19. ADVAGRAF

    Astellas Pharma Inc

    Renal Transplantation

    approved small molecule completed

    1 trial
  20. Ramosetron

    Astellas Pharma Inc

    Irritable Bowel Syndrome

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Astellas Pharma have?

20 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.